The Opdivo from Bristol-Myers Squibb Co. - PD-1 antibody that keeps growing in lung cancer

The Opdivo PD-1 antibody continues to expand its role in non-small cell lung cancer with fresh data and label updates in multiple regions. This bestseller drives the price of Bristol-Myers Squibb shares (ISIN US1078421011).

Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-29, 01:33. Details in the imprint.

The Opdivo vial from Bristol-Myers Squibb sits cold in a hospital fridge, its clear glass catching the fluorescent light while an oncology nurse checks the name twice before hanging it on the drip stand. For many lung cancer patients, this PD-1 antibody has become a quiet, long-term companion to their chemotherapy. The brand has turned from newcomer to everyday tool in oncology wards over the past decade.

How Opdivo is positioned

Opdivo is Bristol-Myers Squibb's nivolumab, a fully human monoclonal antibody that targets the PD-1 receptor on T cells to help the immune system recognise and attack cancer cells. It was first approved in 2014 and has since won indications across melanoma, lung cancer, renal cell carcinoma and several other tumour types. In non-small cell lung cancer, it is used both as monotherapy and in combination with other agents depending on PD-L1 status and disease stage.

In practice, oncologists like Dr Martin Reck in Germany have described nivolumab-based regimens as a consistent backbone in immunotherapy, especially for patients who tolerate long-term infusions reasonably well. On infusion days, patients typically sit in reclining chairs, an IV line taped to the forearm, while the clear solution drips slowly from the Opdivo bag through tubing and into the vein over about 30 minutes or longer, depending on protocol.

Fresh data in lung cancer

In 2024 and 2025, Bristol-Myers Squibb reported new data with Opdivo-based combinations in first-line non-small cell lung cancer, reinforcing overall survival benefits versus platinum-based chemotherapy alone. Several studies focus on patients with PD-L1 expression at different cut-off levels, and the company is working to refine which subgroups see the strongest benefit from nivolumab-containing regimens. Real-world data from registries and hospital networks complement clinical trial results, giving physicians more confidence about safety patterns and durability of response over multiple years of treatment.

For investors, oncology remains a central pillar of Bristol-Myers Squibb's strategy, with Opdivo and the related immuno-oncology portfolio highlighted as key revenue drivers in company presentations. The firm has repeatedly pointed to its lung cancer programmes as an area where incremental trial readouts and label expansions can support medium-term growth in a competitive field dominated by PD-1 and PD-L1 inhibitors from several manufacturers.

How treatment feels for patients

On a typical clinic day, patients arriving for Opdivo infusions often carry a book or tablet, knowing they will spend at least an hour in the chair between pre-med checks and the drip itself. The room usually hums with quiet conversation and the rhythmic beep of infusion pumps, while nurses like Sarah Jenkins adjust flow rates and check blood pressure and oxygen saturation during the session. Many patients report that the physical sensation of the infusion is relatively smooth, with fatigue and mild infusion-related reactions more noticeable later in the day rather than during the drip itself.

From an adherence perspective, oncologists value that nivolumab is given intravenously at regular intervals, making it easier to monitor patients closely and react to immune-related side effects such as rash, colitis or thyroid changes. The hospital setting also allows quick intervention if serious adverse events occur, which is crucial in immunotherapy where overactivation of the immune system can be dangerous if not addressed promptly.

Competition and pipeline context

The PD-1/PD-L1 space is crowded, with competitors such as pembrolizumab and cemiplimab fighting for similar lung cancer segments, keeping pricing and access under pressure. Bristol-Myers Squibb responds by refining combination strategies, for example pairing Opdivo with chemotherapy, CTLA-4 inhibition or other agents in an effort to differentiate outcomes for specific patient subgroups. Newer pipeline assets in immuno-oncology, such as TIGIT or LAG-3 targeted therapies, are being tested alongside nivolumab to see whether multi-pathway blockade can push response rates higher.

Management under CEO Giovanni Caforio has repeatedly underlined immuno-oncology as a core investment area, with Opdivo and related programmes consuming a significant share of R&D spending. Analysts following Bristol-Myers Squibb highlight the need for the company to balance mature brands like Opdivo with newer launches to counter patent expiries and biosimilar threats over the coming years.

What it means for the share price

For hospital pharmacies and oncology centres, Opdivo remains a classic longseller in the immuno-oncology category, with procurement teams tracking both clinical guidelines and reimbursement rules to decide how broadly nivolumab-based regimens are offered. In Europe and the United States, reimbursement decisions by national health systems and private insurers have a direct impact on how many lung cancer patients ultimately receive the drug, which in turn shapes revenue trends reported in Bristol-Myers Squibb's quarterly statements.

Overall, Bristol-Myers Squibb shares (ISIN US1078421011) trade on the NYSE under ticker BMY in US dollars, with the last verified closing price at 57.45 dollars on 2026-06-26.

Key facts on Opdivo

• Product: Opdivo (nivolumab)
• Manufacturer: Bristol-Myers Squibb Company
• Category: Classic longseller oncology drug
• Launch: First regulatory approval in 2014
• RRP / Price: Hospital-negotiated oncology pricing, varies by market and regimen
• Availability: Oncology centres and hospital pharmacies in the US, EU and other major markets
• Target group: Adult patients with specific cancers including non-small cell lung cancer, melanoma and renal cell carcinoma
• Highlight / USP: PD-1 immune checkpoint inhibition with broad label coverage and long-term real-world data

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.